1. Home
  2. ANGO vs ASMB Comparison

ANGO vs ASMB Comparison

Compare ANGO & ASMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AngioDynamics Inc.

ANGO

AngioDynamics Inc.

HOLD

Current Price

$10.60

Market Cap

453.0M

Sector

Health Care

ML Signal

HOLD

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$28.08

Market Cap

440.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ANGO
ASMB
Founded
1988
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
453.0M
440.0M
IPO Year
2004
2010

Fundamental Metrics

Financial Performance
Metric
ANGO
ASMB
Price
$10.60
$28.08
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
6
Target Price
$19.33
$43.40
AVG Volume (30 Days)
266.5K
94.1K
Earning Date
04-07-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
81.92
50.00
EPS
N/A
N/A
Revenue
$291,010,000.00
N/A
Revenue This Year
$9.11
$33.33
Revenue Next Year
$4.94
N/A
P/E Ratio
N/A
N/A
Revenue Growth
10.17
N/A
52 Week Low
$8.36
$7.76
52 Week High
$13.99
$39.71

Technical Indicators

Market Signals
Indicator
ANGO
ASMB
Relative Strength Index (RSI) 40.30 46.78
Support Level $10.37 $26.50
Resistance Level $11.03 $30.66
Average True Range (ATR) 0.36 1.42
MACD -0.06 -0.03
Stochastic Oscillator 10.98 27.35

Price Performance

Historical Comparison
ANGO
ASMB

About ANGO AngioDynamics Inc.

AngioDynamics Inc designs manufactures, and sells medical, surgical, and diagnostic devices used by professional healthcare providers for the treatment of peripheral vascular disease and for use in oncology and surgical settings. Geographically, the company derives a majority of its revenue from the United States from sale of Med Tech and Med Device.

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. It is advancing two platform programs, a novel class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutics, which are designed to restore health to a dysbiotic microbiome. The company's HBV-cure program is aimed at increasing the current low cure rate for patients with HBV and is pursuing multiple drug candidates that inhibit multiple steps of the HBV lifecycle. Assembly has discovered several novel core protein Allosteric Modulators, which are small molecules that directly target and allosterically modulate the HBV core protein. The majority of the revenue is generated from the HBV cure program.

Share on Social Networks: